Launch Precise Oncology Solutions and Precise Tumor
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2022
- Due
- 31 Mar 2022
- Delivered
- 14 Mar 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Launching this quarter”
What we found
Evidence strength A What the grades mean
Myriad Genetics launched Precise Oncology Solutions and the Precise Tumor Molecular Profile Test in March 2022, within the first quarter of 2022 deadline.
-
A Myriad Genetics Inc. 8-K filed 2022-05-05
“In March of 2022, Myriad Genetics launched Precise Tumor for molecular tumor profiling – part of a suite of Precise Oncology Solutions” ✓ confirmed on the page
-
A Myriad Genetics Inc. 10-Q filed 2022-05-06
“On March 14, 2022, we announced the launch of Precise Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treat” ✓ confirmed on the page
Market reaction: the shares moved -2.7% against the S&P 500 over the three sessions around the disclosure (4 May 2022 to 9 May 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Precise Oncology Solutions and Precise Tumor
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-MYGN-003909 · Corrections policy